Plain-English translation of NCT06541860 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →This is a real-world observational study that looks at patients with a difficult-to-treat form of multiple myeloma—a blood cancer that has stopped responding to standard therapies including daratumumab and lenalidomide. Researchers will collect information about what treatments these patients receive next and how well they work, to help doctors make better decisions for future patients facing similar challenges.
When multiple myeloma stops responding to the most common first-line treatments, doctors need better information about which next-step therapies actually help patients survive longer and feel better. This study aims to fill that gap by gathering real-world experience from hospitals treating these hardest-to-treat cases.
You likely qualify if…
You likely don't qualify if…
This is an observational study, meaning you will not receive a new experimental drug—instead, researchers will review your existing medical records and track your care as you receive standard treatment options at your hospital. Your doctors will decide which medication you receive based on what they think is best for you, and the study team will collect information about your outcomes to learn what works for patients in similar situations.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Enrollment target
~100 participants
Started
August 2023
Primary completion
February 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2024.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.